Evidence map›Paper›PMID 37607206›Full record

ArticlePloS one2023

Effect of Test and Treat on clinical outcomes in Nigeria: A national retrospective study.

Marie-Claude C Lavoie, Akipu Ehoche, Natalia Blanco, Ibrahim Ahmed El-Imam, Ademola Oladipo, Ibrahim Dalhatu, Solomon Odafe, Sylvia Adebajo, Alexia H Ng, Laura Rapoport and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Marie-Claude C LavoieDivision of Global Health Sciences, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0003-3315-6207
Akipu EhocheCenter for International Health Education and Biosecurity, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Natalia BlancoInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Ibrahim Ahmed El-ImamCenter for International Health Education and Biosecurity, MGIC-an Affiliate of the University of Maryland Baltimore, Abuja, Nigeria.
Ademola OladipoCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Ibrahim DalhatuCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Solomon OdafeCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Sylvia AdebajoCenter for International Health Education and Biosecurity, MGIC-an Affiliate of the University of Maryland Baltimore, Abuja, Nigeria.
Alexia H NgCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.ORCID 0000-0002-9948-5663
Laura RapoportInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Jonathan G LawtonInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Christopher ObanubiCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Denis OnotuCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Sadhna PatelCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Akudo IkpeazuNational AIDS and STI Control Programme-Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.ORCID 0000-0002-0654-2201
Greg AsheforNational Agency for the Control of AIDS, Abuja, Nigeria.
Bashorun AdebobolaNational AIDS and STI Control Programme-Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
Mary Adetinuke BoydCenters for Disease Control and Prevention, CGH/DGHT, Abuja, Nigeria.
Gambo AliyuNational Agency for the Control of AIDS, Abuja, Nigeria.
Kristen A StaffordDivision of Global Health Sciences, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0001-5620-6436
Nigeria Centre for Disease Control · NGUniversity of Maryland, Baltimore · USFederal Ministry of Health · NGNational Agency for the Control of AIDS · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Nigeria, results from the pilot of the Test and Treat strategy showed higher loss to follow up (LTFU) among people living with HIV compared to before its implementation. The aim of this evaluation was to assess the effects of antiretroviral therapy (ART) initiation within 14 days on LTFU at 12 months and viral suppression.

methodsWe conducted a retrospective cohort study using routinely collected de-identified patient-level data hosted on the Nigeria National Data Repository from 1,007 facilities. The study population included people living with HIV age ≥15. We used multivariable Cox proportional frailty hazard models to assess time to LTFU comparing ART initiation strategy and multivariable log-binomial regression for viral suppression.

resultsOverall, 26,937 (38.13%) were LTFU at 12 months. Among individuals initiated within 14 days, 38.4% were LTFU by 12 months compared to 35.4% for individuals initiated >14 days (p<0.001). In the adjusted analysis, individuals who were initiated ≤14 days after HIV diagnosis had a higher hazard of being LTFU (aHR 1.15, 95% CI 1.10-1.20) than individuals initiated after 14 days of HIV diagnosis. Among individuals with viral load results, 86.2% were virally suppressed. The adjusted risk ratio for viral suppression among individuals who were initiated ≤14 days compared to >14 days was not statistically significant.

conclusionLTFU was higher among individuals who were initiated within 14 days compared to greater than 14 days after HIV diagnosis. There was no difference for viral suppression. The provision of early tailored interventions to support newly diagnosed people living may contribute to reducing LTFU.

Indexed as

CognitionFrailtyEarly Intervention, EducationalHumansNigeriaRetrospective Studies

Identifiers

PMID37607206
PMCPMC10443836
OpenAlexW4386065323

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.